corticosterone has been researched along with Pituitary ACTH Hypersecretion in 7 studies
Pituitary ACTH Hypersecretion: A disease of the PITUITARY GLAND characterized by the excess amount of ADRENOCORTICOTROPIC HORMONE secreted. This leads to hypersecretion of cortisol (HYDROCORTISONE) by the ADRENAL GLANDS resulting in CUSHING SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gefitinib treatment decreased both tumor size and corticosterone levels; it also reversed signs of hypercortisolemia, including elevated glucose levels and excess omental fat." | 1.37 | EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. ( Ben-Shlomo, A; Bruyette, D; Cooper, O; Fukuoka, H; Mamelak, A; Melmed, S; Ren, SG, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berthon, A | 1 |
| Faucz, FR | 1 |
| Espiard, S | 1 |
| Drougat, L | 1 |
| Bertherat, J | 1 |
| Stratakis, CA | 1 |
| Page-Wilson, G | 1 |
| Peters, JB | 1 |
| Panigrahi, SK | 1 |
| Jacobs, TP | 1 |
| Korner, J | 1 |
| Otten, M | 1 |
| Bruce, JN | 1 |
| Wardlaw, SL | 1 |
| Du, L | 1 |
| Bergsneider, M | 1 |
| Mirsadraei, L | 1 |
| Young, SH | 1 |
| Jonker, JW | 1 |
| Downes, M | 1 |
| Yong, WH | 1 |
| Evans, RM | 1 |
| Heaney, AP | 1 |
| Feldhaus, AL | 1 |
| Anderson, K | 1 |
| Dutzar, B | 1 |
| Ojala, E | 1 |
| McNeill, PD | 1 |
| Fan, P | 1 |
| Mulligan, J | 1 |
| Marzolf, S | 1 |
| Karasek, C | 1 |
| Scalley-Kim, M | 1 |
| Stewart, E | 1 |
| Billgren, J | 1 |
| Rubin, V | 1 |
| Schneider, K | 1 |
| Jurchen, D | 1 |
| Snow, K | 1 |
| Barnett, S | 1 |
| Bengtsson, B | 1 |
| Baker, B | 1 |
| Latham, JA | 1 |
| Allison, D | 1 |
| Garcia-Martinez, LF | 1 |
| Scheithauer, BW | 1 |
| Kovacs, K | 1 |
| Horvath, E | 1 |
| Kim, DS | 1 |
| Osamura, RY | 1 |
| Ketterling, RP | 1 |
| Lloyd, RV | 1 |
| Kim, OL | 1 |
| Liu, NA | 1 |
| Jiang, H | 1 |
| Ben-Shlomo, A | 2 |
| Wawrowsky, K | 1 |
| Fan, XM | 1 |
| Lin, S | 1 |
| Melmed, S | 2 |
| Fukuoka, H | 1 |
| Cooper, O | 1 |
| Mamelak, A | 1 |
| Ren, SG | 1 |
| Bruyette, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease[NCT03774446] | Phase 2 | 13 participants (Anticipated) | Interventional | 2018-11-02 | Recruiting | ||
| Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine[NCT02160730] | Phase 2 | 4 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to NIH grant ended.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of participants that achieved a urinary free cortisol level above the upper limit of the normal range but reduced by ≥50% from baseline at week 4. (NCT02160730)
Timeframe: Baseline, Week 4
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 2 |
A visible change in tumor size as determined by the investigator after reviewing MRI reports between baseline and 4 weeks of treatment. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 0 |
"To evaluate the efficacy of R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks on normalizing 24 hour urinary free cortisol (24 h UFC) levels in CD patients. Normalizing is defined as having urine free cortisol levels within the normal range for that lab value." (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 0 |
The number of participants that experience an adverse event between baseline and study end likely related to study drug as a measure of safety and tolerability. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 2 |
Change in typical Cushing's syndrome clinical signs and symptoms defined by mean weight at baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | lbs (Mean) | |
|---|---|---|
| Baseline | 4 Weeks | |
| R-roscovitine | 217 | 217.4 |
Mean diastolic blood pressure between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | 4 Weeks | |
| R-roscovitine | 76.5 | 71 |
HbA1c levels are measured at baseline and at study end, these are averaged across all subjects. (NCT02160730)
Timeframe: Baseline, 4 Weeks
| Intervention | Percentage (Mean) | |
|---|---|---|
| Baseline | Study End-4 weeks | |
| R-roscovitine | 6.9 | 7 |
Mean change in systolic blood pressure between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | 4 weeks | |
| R-roscovitine | 150.3 | 128.3 |
Mean serum cortisol values at baseline and 4 weeks (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline | 4 Weeks | |
| R-roscovitine | 25.6 | 27.1 |
Mean change between baseline and week 4 of fasting blood glucose levels. (NCT02160730)
Timeframe: Baseline, 4 Weeks
| Intervention | g/dL (Mean) | |
|---|---|---|
| Baseline | 4 weeks | |
| R-roscovitine | 121.4 | 104.3 |
Mean change in Plasma ACTH between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Baseline | 4 weeks | |
| R-roscovitine | 79.3 | 79.9 |
7 other studies available for corticosterone and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
Age-dependent effects of Armc5 haploinsufficiency on adrenocortical function.
Topics: Adrenal Cortex; Adrenal Glands; Adrenocortical Hyperfunction; Age Factors; Animals; Armadillo Domain | 2017 |
Plasma Agouti-Related Protein and Cortisol Levels in Cushing Disease: Evidence for the Regulation of Agouti-Related Protein by Glucocorticoids in Humans.
Topics: Adult; Aged; Agouti-Related Protein; Animals; Corticosterone; Female; Glucocorticoids; Humans; Hydro | 2019 |
Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease.
Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Animals; Cell Line, Tumor; Cell Proli | 2013 |
ALD1613, a Novel Long-Acting Monoclonal Antibody to Control ACTH-Driven Pharmacology.
Topics: Adrenal Hyperplasia, Congenital; Adrenocorticotropic Hormone; Animals; Antibodies, Monoclonal; Antib | 2017 |
Pituitary blastoma.
Topics: Adrenocorticotropic Hormone; Corticosterone; Diabetes Insipidus; Diagnosis, Differential; Female; Hu | 2008 |
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.
Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Animals; Animals, Genetically Modifie | 2011 |
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.
Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Animals; Animals, Genetically Modifie | 2011 |
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.
Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Animals; Animals, Genetically Modifie | 2011 |
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.
Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Animals; Animals, Genetically Modifie | 2011 |
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Animals; Cell Line, Tumor; C | 2011 |